Co-Authors
This is a "connection" page, showing publications co-authored by Salim Virani and Erin Michos.
Connection Strength
0.775
-
Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. Circulation. 2019 01 15; 139(3):410-412.
Score: 0.201
-
Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: Insights from the Department of Veterans Affairs. Vasc Med. 2018 06; 23(3):232-240.
Score: 0.190
-
Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs. Circulation. 2017 06 20; 135(25):2572-2574.
Score: 0.179
-
Same evidence, varying viewpoints: Three questions illustrating important differences between United States and European cholesterol guideline recommendations. Am J Prev Cardiol. 2020 Dec; 4:100117.
Score: 0.057
-
Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: A scientific statement from the American Society for Preventive Cardiology. Am J Prev Cardiol. 2020 Mar; 1:100009.
Score: 0.055
-
Life's Simple 7 and the risk of atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2018 08; 275:174-181.
Score: 0.048
-
Life's Simple 7 and Incident Heart Failure: The Multi-Ethnic Study of Atherosclerosis. J Am Heart Assoc. 2017 Jun 27; 6(6).
Score: 0.045